Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether the combination of semaglutide
(SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR) causes
fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants ...
Age: 18 - 80 years
Gender: All
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and
Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Age: 18 years - 66+
Gender: All
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
This study will compare the effects of AXA1125, an orally active mixture of amino acids,
compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis
in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tol...
Age: 18 years - 66+
Gender: All
A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis stage 2 or 3
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression
of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an
accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing l...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter,
parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability
of belapectin compared with placebo in patients with nonalcoholic steatohepatitis (NAS...
Age: 18 - 75 years
Gender: All
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic
performance of CT1 at discriminating those with NAS≥4 & F≥2 from those without.
Age: 18 - 75 years
Gender: All
The Liver in the World Trade Center Health Program General Responder Cohort and Controls
This project investigates whether exposure to the World Trade Center Attack is a risk factor
for liver injury.
Age: 55 - 80 years
Gender: All
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747)
can lead to histological improvement in fibrosis with no worsening of NASH in adults with
compensated cirrhosis due to NASH.
Age: 18 years - 66+
Gender: All